Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A recent clinical trial found that the combination did not work.
The agency also announced the qualification of a tool to aid in the effectiveness assessment of devices used in breast reconstruction.
New drugsto treat multiple myeloma are producing better results for patients, with fewer side effects.
This represents an important advance for patients who previously needed to visit a health care facility.
Project Patient Voice is going to provide patient-reported symptoms from cancer trials for marketed treatments.
These are the latest cancer treatments approved by the FDA.
FDA advises consumers, patients and health care professionals after new FDA studies show risk to public health.
The FDA offers researchers new guidance to help keep trials on track.
Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.
Approval was based on a study showing combination treatment reduced disease progression or death by 40%.
A third of people treated with Nerlynx plus capecitabine experienced remission.
The agency reviewed a decade of animal and epidemiological studies in search of such evidence.
Potential risk of cancer outweighs the benefits
The National Cancer Institute stands to lose more than $500 million, and cancer prevention programs are at risk.
Epithelioid sarcoma is a rare sub-type of soft tissue sarcoma that often occurs in young adults.
New research adds to our understanding of sunscreens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.